Updated on 23 January 2015
Novotech began operations in Hong Kong in 2013
Singapore: Australia-based contract research organization, Novotech, recently announced that it has expanded its Hong Kong operation with a permanent office and new staff, inorder to meet the growing demand for clinical research in the country.
The company began operations in Hong Kong in 2013.
Dr John Moller, chief scientific officer, Asia, Novotech, said, "The relocation to a larger office aimed at meeting growing demand from drug companies as the pharmaceutical industry in the region is thriving."
Dr Moller further added that Hong Kong is a significant market in high demand from the US and the Europe based pharma and biotech companies. The city is also recognized officially by the CFDA to conduct clinical trials in Mainland China in certain therapeutic areas, he said.
"We will conduct more phase I trials following the opening of Phase 1 centers at some universities in Hong Kong, said Dr Moller, "in the next few years, we also see a need to expand our workforce by recruiting experts locally to meet with our business expansion."
Mr Charkles Ng, associate director-general, Invest Hong Kong, said, "The country is a leading medical and pharmaceutical center in Asia. The country also has experts in different disciplines of clinical trials, and this can help foreign companies like Novotech to establish and strengthen their footprint in Asia."